Article Text

other Versions

PDF
The role of endomyocardial biopsy in the management of cardiovascular disease: A commentary on joint AHA/ACC/ESC guidelines.
  1. Perry M Elliott (perry.elliott{at}ucl.ac.uk)
  1. University College London, United Kingdom
    1. Eloisa Arbustini (e.arbustini{at}smatteo.pv.it)
    1. San Matteo Hospital, Pavia, Italy

      Abstract

      Data on the use of endomyocardial biopsy (EMB) in routine cardiological practice are scant, but anecdotal evidence suggests that its frequency varies substantially between centres. The reasons for this variation are unclear, but they almost certainly include differential access to cardiological and pathological expertise and a lack of consensus on the risk-benefit ratio of EMB in particular clinical situations. A distinguished panel working under the auspices of the American Heart Association (AHA), American College of Cardiology (ACC) and the European Society of Cardiology (ESC) have recently produced a scientific statement on the indications for EMB. In this commentary, we review the risks discuss their recommendations in the context of current cardiological practice.

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.